Hematologic Malignancies

Individualizing Care for Multiple Myeloma: Navigating Treatment Options and Addressing Patient Needs

Presented by Beth Finley-Oliver, MSN, ARNP, AGNP-BC, and Rachid Baz, MD

At JADPRO Live 2023 in Orlando, presenters discussed selecting treatment regimens for newly diagnosed and relapsed or refractory multiple myeloma. They also provided insights on comprehensive care centered around patient preferences, tre...

A Comprehensive Bone Marrow Aspirate and Biopsy Educational Program Utilizing Task Trainers

Jessica Casselberry, DNP, ANP-BC, AOCNP®, and Jennifer Fisher, DNP, WHNP

Background: Advanced practice providers (APPs) who care for patients with hematologic malignancies perform bone marrow aspiration and biopsies (BMBXs). Invasive bedside procedures are often taught through the observational training metho...

Role of Preemptive Cytomegalovirus Hyperimmunoglobulin in Cytomegalovirus Viremia Following Stem Cell Transplant: An Integrative Review

Jaci Whittaker, MSN, APRN, FNP-BC, Ashley Martinez, DNP, APRN, FNP-BC, and Joyce E. Dains, DrPH, JD, APRN, FNP-BC, FANP, FAANP, FAAN

Introduction: Cytomegalovirus (CMV) is a major cause of morbidity and mortality in stem cell transplant (SCT) patients. Cytomegalovirus hyperimmunoglobulin (CMV-HIG) therapy has been described in the solid organ transplant setting. Howev...

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma

Rakesh Popat,(1) BSc, MBBS, MRCP, FRCPath, PhD, Sagar Lonial,(2) MD, FACP, Peter M. Voorhees,(3) MD, Simona Degli Esposti,(4) MD, Boris Gorsh,(5a) PharmD, Ira Gupta,(5a) MD, Joanna Opalinska,(5) PhD, Sandhya Sapra,(5) PhD, Trisha Piontek,(5) BS, RN, Zangdong He,(5) PhD, David Kleinman,(6) MD, MBA, Debra Schaumberg,(7) SCD, OD, MPH, Antoine Regnault,(8) PhD, Juliette Meunier,(8) MSc, and Laurie Eliason,(5a) MPH

In the randomized phase II DREAMM-2 study, single-agent belantamab mafodotin demonstrated deep and durable responses and a manageable safety profile in triple-class refractory relapsed/refractory multiple myeloma (RRMM). We present patie...

Post-Transplant Cyclophosphamide for the Prevention of Graft-vs.-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Guide to Management for the Advanced Practitioner

Ekaterina Kachur, PharmD, BCOP, Jai N. Patel, PharmD, BCOP, CPP, Allison L. Morse, PharmD, BCOP, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, and Justin R. Arnall, PharmD, BCOP

Cyclophosphamide remains a critical component to haploidentical transplant conditioning regimens. Post-transplant cyclophosphamide (PTCy) emerged as an effective component of graft-vs.-host disease (GVHD) prophylaxis in the nonmyeloablat...

Knowing Your Target: Altered Mental Status From an Unsuspected Source

Sarah Hemstetter, MSN, CRNP, AOCNP®

Daratumumab is a human monoclonal antibody targeting CD38 that is used in the treatment of multiple myeloma. In addition to being a target for cancer-related treatment, CD38 also plays a significant role in the immune response to infecti...

Anti-Spike Antibody Responses in Allogeneic Stem Cell Transplant Recipients to Two Doses of COVID-19 mRNA Vaccination: A Retrospective, Single-Center Analysis

Jaime L. Shahan, MPAS, PA-C, Robert H. Collins, MD, Prapti Patel, MD, Yazan F. Madanat, MD, and Madhuri Vusirikala, MD

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients were excluded from the initial SARS-CoV-2 mRNA vaccination efficacy trials. Suboptimal vaccine responses have been reported in immunocompromised cohorts such as pa...

Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin

Rebecca Lu, MSN, FNP-C, Ashley Morphey, RN, MSN, CCRP, Felicia Diaz, MSN, APRN, FNP-BC, AOCNP®, Jessica Chen, RN, MSN, OCN®, FNP-C, Azadeh Razmandi, OD, FAAO, and Tiffany Richards, PhD, ANP-BC, AOCNP®

While significant strides have been made in the treatment of multiple myeloma, treatment options remain limited and definite, and most patients ultimately succumb to their disease. The urgency for more treatment modalities remains, as pa...

Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma

Presented by Cesar Rodriguez, MD, and Donna Catamero, ANP-BC, OCN®, CCRC

Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by genetic and cytogenetic alterations th...

Physical Activity in Multiple Myeloma: A Review of the Current Literature

Michaela Hillengass,(1) RN, ACSM-CPT, Janine Joseph,(1) MS, MBA, Jane McCarthy, and Jens Hillengass,(1) MD, PhD

One of the major issues patients with multiple myeloma (MM) suffer from is bone instability and the resulting difficulties that come along with it, such as pain and immobility. Few studies have been performed in this patient group to inv...

Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Gwen Hua,(1) PharmD, BCOP, Ryan Scanlan,(2) PharmD Candidate, Rachael Straining,(1) PharmD, BCOP, and Daniel S. Carlson,(3) DO

Multiple myeloma (MM) remains an incurable malignancy originating from plasma cells. Despite significant advances in treatment, relapses remain inevitable, and novel therapies continue to be needed. Teclistamab-cqyv is a first-in-class, ...

The Role of the Research Advanced Practice Provider in CAR T-Cell Clinical Trials

Ly Dsouza, PA-C, MPAS

In recent years, chimeric antigen receptor (CAR) T-cell therapy has emerged as an effective and potentially paradigm-shifting therapy for patients with refractory lymphoma and myeloma. This novel therapy involves engineering T cells to r...

Development of a Standardized Bone Marrow Procedure Training and Competency Toolkit for Advanced Practice Providers in a Large Community Oncology Practice

Katharine Lord,(1) PA-C, Sara Toth,(2) APRN, FNP-C, AOCNP®, AGN-BC, Jennifer Potter,(3) PA-C, Katherine Sellers,(4) PA-C, Monica White,(5) APRN, CNS-AH, ACNP-BC, AOCNP®, Anne Neugent,(4) APRN, FNP-C, and Tracy Martin,(4) APRN, ANP-C, AOCNP®, BMTCN, NursEd

Bone marrow procedures are a common diagnostic tool utilized in hematology/oncology and can be completed in the office by trained clinicians. Currently, there are limited guidelines for appropriate training and competency for bone marrow...

Hematologic Malignancies: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

P. Andrew Allred, MS, PA-C, Amy Pierre, MSN, ANP-BC, Meredith Beaton, MSN, RN, Pamela Lee, NP, MSN, and Amber Koehler, PA-C

P. Andrew Allred, MS, PA-C, of Banner MD Anderson Cancer Center, considers data on managing newly diagnosed MM and CAR T-cell therapy in MM. Amy Pierre, MSN, ANP-BC, of MSKCC and Flatiron Health, reviews findings on telemedicine inequiti...

Molecular Testing in Hematologic Malignancies

Laura J. Zitella, MS, RN, ACNP-BC, AOCN®

Molecular testing technologies have been increasingly integrated into clinical research and are essential tools in the care of patients with hematologic malignancies. During this session at JADPRO Live Virtual 2021, Laura J. Zitella, MS,...

New Frontiers: The Role of CAR T-Cell Therapy in Multiple Myeloma

Alli McClanahan, APRN, and Megan Spychalla, PA-C

Multiple myeloma remains the second most common hematologic malignancy, and relapse rates are high, with refractory disease common with each relapse. Chimeric antigen receptor (CAR)–modified T cells are a promising new treatment, and at ...

Antibiotic Therapy and Gastrointestinal Graft-Versus-Host Disease in the Allogeneic Stem Cell Transplantation Population

Jessica Thomas, MSN, APRN, FNP-C, AOCNP®, Christi Bowe, MSN, APRN, ANP-C, and Joyce E. Dains, DrPH, JD, APRN, FNP-BC, FNAP, FAANP

Purpose: Hematopoietic stem cell transplantation patients undergo rigorous courses of myeloablative chemotherapy that increase vulnerability for infections. Complications can arise in the form of graft-vs.-host disease (GvHD) manifesting...

Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Emily Behren Ketchum, PharmD, Andrea Clarke, PharmD, BCOP, and Amber B. Clemmons, PharmD, BCOP

Multiple myeloma (MM) is a hematologic malignancy characterized by proliferation of plasma cells with or without production of monoclonal immunoglobulins. Management of patients with MM begins with induction therapy, typically a proteaso...

Development and Implementation of an Advanced Practitioner–Led Survivorship Clinic for Patients Status Post Allogeneic Transplant

Linda K. Baer,(1) MSN, APRN, AOCNP®, Lauren Brister,(1) MSN, APRN, AOCNP®, and Susan R. Mazanec,(1,2) PhD, RN, AOCN®, FAAN

Background: Survivor recovery from hematopoietic cell transplantation (HCT) is long term, with significant physical and psychological morbidities that impact quality of life and reentry into personal and social lives. The optimal timing ...

Short- and Long-Term Outcomes of Hematologic Malignancy Patients After Cardiopulmonary Resuscitation: Experience of a Large Oncology Center

Mary Lou Warren, DNP, APRN, CNS-CC, FCCM, Virginia V. Schneider, MPAS, PA-C, Yun Qing, MHS, PhD, Lei Feng, MS, Jeanne Y. Campbell, MPAS, PA-C, Jason W. Myers, ACNP-BC, Marian Von-Maszewski, MD, and Cristina Gutierrez, MD

Purpose: The objective of this study is to describe characteristics and short- and long-term outcomes of patients with hematologic malignancies who received cardiopulmonary resuscitation (CPR). Methods: A retrospective review was conduct...

Hematologic Malignancies: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Amber B. Koehler, PA-C, MS, P. Andrew Allred, MS, PA-C, and Donna Catamero, ANP-BC, OCN®, CCRC

With conference reporting provided by The ASCO Post, Amber B. Koehler, PA-C, MS, of Mayo Clinic, evaluates data on BTK inhibitors; fixed-duration, first-line treatment with ibrutinib plus venetoclax; and a novel oral BCL2 antagonist for ...

Diagnosis and Treatment of AL and ATTR Amyloidosis

Presented by Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN, and Tiffany Richards, PhD, ANP-BC, AOCNP®

At JADPRO Live Virtual 2020, Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN, and Tiffany Richards, PhD, ANP-BC, AOCNP®, differentiated between AL and ATTR amyloidosis, discussed key considerations in selecting therapy, and identified wa...

Improving Outcomes in Hematopoietic Stem Cell Transplant: Recent Advances

Presented by Maritza Alencar, DNP, MBA, APRN-BC, BMTCN

During JADPRO Live Virtual 2020, Maritza Alencar, DNP, MBA, APRN-BC, BMTCN, described advances in the management and prevention of infectious disease complications and graft-vs.-host disease following transplant. Dr. Alencar also emphasi...

Hematologic Malignancies: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Amy Pierre,(1) MSN, ANP-BC, P. Andrew Allred,(2) MS, PA-C, and Allyson Price,(3) PA-C

Amy Pierre, MSN, ANP-BC, of Memorial Sloan Kettering Cancer Center, P. Andrew Allred, MS, PA-C, of Banner MD Anderson Cancer Center, and Allyson Price, PA-C, of MD Anderson Cancer Center, provide expert insights for advanced practitioner...

Patient-Reported Outcomes and Assessment of Quality of Life: A Focus on Multiple Myeloma

MaryAnn Fragola, ANP-C, DNP

Patients with multiple myeloma are living longer, yet the chronicity of newer treatment modalities has led to increased symptom burden and a notable effect on quality of life (QOL). The assessment of QOL and evaluation of patient-reporte...

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma

Presented by Edward Libby,(1) MD, and Josh Epworth,(2) ARNP

Edward Libby, MD, and Josh Epworth, ARNP, interpreted data on current and novel treatments, discussed how to select initial therapy based on patient risk and in alignment with guidelines and best practices, and evaluated the use of minim...

Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple Myeloma

Presented by Amy E. Pierre,(1) MSN, ANP-BC, and Joshua Richter,(2) MD

Amy E. Pierre, MSN, ANP-BC, and Joshua Richter, MD, break down the approved and emerging treatment options for relapsed/refractory multiple myeloma, including mechanisms of action, supporting clinical data, and associated adverse events,...

AL Amyloidosis: Unfolding a Complex Disease

Rebecca Lu, MS, FNP, and Tiffany A. Richards, PhD, ANP-BC

Light chain (AL) amyloidosis is a rare plasma cell dyscrasia. An estimated 12,000 people live with the disease in the United States. AL amyloidosis occurs from the misfolding of proteins that deposit in organs (heart, kidneys, digestive ...

Aztreonam and Vancomycin for Initial Treatment of Febrile Neutropenia in Penicillin-Allergic Patients During Hematopoietic Stem Cell Transplantation

Steven Trifilio, RPh, and Jayesh Mehta, MD

Most patients who undergo hematopoietic stem cell transplantation develop neutropenic fever and are at high risk for developing potentially life-threatening infections. β-lactam antibiotics remain the cornerstone for initial empiric trea...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Hematologic Malignancies

Amy Pierre, MSN, ANP-BC, and Nancy M. Nix, PharmD, BCPS, BCOP

Amy Pierre, MSN, ANP-BC, of the Memorial Sloan Kettering Cancer Center, and Nancy M. Nix, PharmD, BCPS, BCOP of St. Joseph’s/Candler Health System offer an advanced practitioner perspective on trials assessing the efficacy and safety of ...

Immunoglobulin Light-Chain Amyloidosis: Clinical Presentations and Diagnostic Approach

Yi L. Hwa, DNP,(1) Teresa Fogaren, MSN, AGNP-C,(2) Allison Sams, AGPCNP-BC,(3) Douglas V. Faller, MD, PhD,(4) Dawn M. Stull, PharmD, BCOP,(5) Sara Thuenemann, RN, MSN, DHSc,(6) and Lisa Mendelson, MSN, AGPCNP-BC(7)

Abstract Systemic immunoglobulin light-chain (AL) amyloidosis is a rare disorder arising from a plasma cell clone that produces misfolded immunoglobulin light chains, which are deposited in various tissues and organs as amyloid fibrils....

Advances in the Management of Myeloma

Presented by Beth Faiman, PhD, MSN, APRN-BC, AOCN®, and Rachid Baz, MD

New agents for the treatment of myeloma have individual and class effects that advanced practitioners need to know about when helping to keep their patients on treatment regimens. At JADPRO Live, Beth Faiman, PhD, MSN, APRN-BC, AOCN®, an...

Differential Diagnosis and Testing for Hematologic Malignancies

Presented by Sandra E. Kurtin, PhD, ANP-C, AOCN®, and Jennifer Knight, MD

Sandra E. Kurtin, PhD, ANP-C, AOCN®, and Jennifer Knight, MD, provided advice to the advanced practitioner audience on appropriately applying diagnostic tests in order to acquire actionable information about a patient’s disease.

Multiple Myeloma: Risk Stratification and Toxicity Management

The treatment landscape for multiple myeloma is rapidly changing. At JADPRO Live 2017, presenters brought advanced practitioners up to date on the newest approaches to the management of this disease, as well as what to be aware of when t...

An Anecdotal Outpatient Approach to Caring for Patients With End-Stage Hematologic Malignancies

Abstract Historically, hospice has been a poor option for patients with end-stage hematologic malignancies, largely due to the need for regular transfusions to sustain life near the end, and to a lesser extent the treatment of curable e...

Integrating Emerging Data Into Clinical Practice: A Case-Based Approach for Multiple Myeloma

Selected Patient Cases From the APSHO Regional Lecture Series Introduction As the official publication of the Advanced Practitioner Society for Hematology and Oncology (APSHO), JADPRO is pleased to offer Part 2 of an accredited educa...

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma

The FDA approval of ixazomib for use in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy signalled the arrival of the first oral proteasome inhibitor, allowin...

New Treatment Strategies Making an Impact in Multiple Myeloma

Even though multiple myeloma remains incurable, mean overall survival has improved dramatically as newer game-changing therapies enter the scene. At the same time, treatment decisions and the management of toxicities related to newer dru...

Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?

Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma

Risk Stratification in Multiple Myeloma: Putting the Pieces Together